




Development of Tannic acid/Al (III) Nanoparticles  
for Controlled Release of Liraglutide:  






A thesis submitted to Johns Hopkins University in conformity with the 
requirements for the degree of Master of Science in Engineering.  
 




© 2019 Jinchang Zhu 






Liraglutide is a GLP-1 agonist recently approved for treating Type-II diabetes. Its clinical 
application for treating Type II diabetes has been very limited due to its short half-life time of 
around 13 h. In this study, we developed a ternary component nanoparticle platform of 
liraglutide/tannic acid/Al3+ for sustained release of liraglutide, where tannic acid and liraglutide 
form complexes and Al3+ served as an additional crosslinking agent. Liraglutide was 
encapsulated with a high efficiency (98%) and size uniformity of nanoparticles with a z-average 
size of 55 nm and a PDI of 0.16 using flash nanocomplexation (FNC) method. This method 
enables the turbulent mixing that prevented the aggregation of nanoparticles during the 
preparation. The optimized nanoparticles showed a sustained release profile for 7 days in vitro 
and 6 days in vivo following intraperitoneal injection; and it was capable of suppressing the 
glucose level of T2D mice under 50% of original level for 84 hours. Notably, by controlling the 
amount of tannic acid incorporated in the nanoparticles, the release behavior was tunable and 
led to significant difference of treatment outcomes in T2D mice. The scalable production 
capability of this manufacturing process and tunable release profile render these 
liraglutide/tannic acid/Al3+ ternary nanoparticles a promising system in future clinical 
translation. 
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Diabetes mellitus, a chronic disease with 415 million adult patients globally, has become the 
ninth major cause of death, in which 90% of cases are type 2 diabetes (T2D) [1]. Compared 
with non-diabetic counterparts, patients with T2D suffer from higher risk of cardiovascular 
disease (CVD), which accounts for the largest proportion (80%) of deaths cause in T2D [2, 3]. 
Therefore, cardiovascular (CV) safety has been listed as a criterion in the assessment for anti-
diabetic agents. As increasing number of new anti-diabetic drugs are entering clinical trials, 
cardiovascular benefits are receiving attention as a trend of drug assessment. It requires anti-
diabetic drugs not only to manage blood sugar, but also to improve cardiovascular functions. 
Liraglutide (brand name Victoza), as the only glucagon-like peptide-1 (GLP-1) drug tagged by 
FDA with specific label indicating CV benefits, is approved to reduce the risk of major CV 
events including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in 
T2D patient groups [4]. However, clinical application of liraglutide is hindered due to its high 
dose frequency (1 dose/day) and short half-life time (13 h), compared with other long-acting 
GLP-1 anti-diabetic drugs like dulaglutide (brand name Trulicity), with dose frequency of 1 
dose/week. In order to prolong the acting time, pharmaceutical excipients are applied to dosage 
form. A microsphere formulation for extended release of exenatide (brand name Bydureon) has 
been approved by FDA in 2017. 
 
Some progress, especially formulations for sustained release, has been made to enhance the 
clinical outcomes of liraglutide [5-10]. Semaglutide (brand name Ozempic), a chemical 




life time to 46 h at a cost of 3-fold decrease in affinity with GLP-1 receptor[10]. In addition, 
following the microsphere formulation of exenatide, liraglutide was similarly encapsulated in 
the poly(lactic acid-co-glycolic acid) microparticles, achieving a 20-day release[9]. However, 
it suffered from relative low encapsulation efficiency (<80%) and complexed preparation, 
which pose challenge on industrial translation. Besides beads and particles, hydrogel was also 
applied to long-term release of peptide. Injectable polymeric solution carrying liraglutide 
formed in-situ hydrogel in vivo after subcutaneous (s.c.) injection and made a sustained release 
of drug [6]. Nevertheless, the degradation time of the hydrogel lags 2 to 3 times longer than the 
drug-release time, which leads to accumulation of the left-over materials, and posed a challenge 
to multiple-dose administration in a long-term treatment.  
 
In this study, we aimed to provide a nanoparticle (NP)-based therapeutic formulation, which 
combines the following advantages: (i) controlled release of liraglutide with tunable release 
durations; (ii) facile and scalable process with high reproducibility; and (iii) feasibility of 
multiple injections for potential clinical application. We designed a tannic acid (TA)/liraglutide 
(Lira)/Al3+ ternary system where peptides and TA form hydrogen bonding and Al3+ serves as a 
crosslinker by complex coordinate bonding with TA. TA is a natural plant polyphenol with pKa 
around 6, is approved by FDA to be applied as food additives. It forms complex with proteins 
and peptides based on strong interaction of hydrogen bonding. We assumed that the complex 
state extended the half-life time of Lira [11]. In subcutaneous and intraperitoneal environment, 
where pH is around 7.4, the interaction is weakened due to ionization of phenol groups on TA, 




nanocomplexation (FNC) technique, where TA, Lira and Al3+ are mixed rapidly through 
turbulent flow formation (the characteristic mixing time < 50 msec). This mixing method 
enables homogeneous formation of NPs in a confined impinging jet (CIJ) chamber. We 
highlighted and analyzed the role of FNC involved in the particle assembly and the benefit it 
brought to preparation. Besides the prolonged release, we successfully controlled the release 
behavior by regulating the component amount of TA and the assessed performance of different 
formulations in managing blood glucose level of T2D animal model.  
 
2. Materials and methods 
2.1 Materials 
Liraglutide was purchased from Taiye Biopharmaceuticals Co. Ltd. (China). Tannic acid and 
aluminum chloride hexahydrate (AlCl3·6H2O) were purchased from Sigma Aldrich. Vivaspin® 
500 ultrafiltration tubes (300kDa MWCO) were purchased from Sartorius (USA). Float-A-
Lyzer® G2 Dialysis Tube (300kDa MWCO) was purchased from Spectrum Labs (USA). 
NanoOrange Protein Quantitation Kit was purchased from Thermo Fisher Scientific (USA). 
Cyanine 7.5 (Cy 7.5) NHS ester was purchased from Lumi-Probe (USA). NanoOrange Protein 
Quantitation Kit was purchased from Thermo Fisher Scientific (USA).  
 
2.2 FNC setup and preparation of Lira-loaded nanoparticles 
A three-inlet CIJ mixer was configured as the platform for FNC (Fig. 3A). Controlled by digital 
syringe pumps (New ERA, NE-4000, USA), solution of Lira, TA and Al3+ were injected into 




of NPs solution (1 ml) was discarded, which may contain nonuniformly mixed components. 
Working solutions were prepared as follows: (i) Lira was dissolved in deionized (DI) water at 
a concentration of 1 mg/mL and titrate to pH 7.4 with 10 mM NaOH; (ii) In case of metallic 
hydrolyzation, AlCl3·6H2O solution was generated by diluting the primary solution (1 mg/mL, 
pH 2.0) with DI water to the concentration of 0.05 mg/mL, followed by pH regulation to 2.0. 
(iii) TA was dissolved in 50 mM HEPES (pH=5.0) at concentration of 0.5, 1.0 and 2.0 mg/mL. 
Formulations with TA concentration of 0.5, 1.0 and 2.0 mg/mL were referred to as NPs-1, NPs-
2 and NPs-3 respectively. 
 
2.3 Nanoparticle characterization 
Size distribution, polydispersity index (PDI) and zeta-potential of NPs were characterized by 
dynamic light scattering (DLS) and phase analysis light scattering (PALS) (Zetasizer Nano ZS, 
Malvern). The morphology was characterized by transmission electron microscopy (TEM) 
(Tecnai 12, FEI). Encapsulation efficiency was measured by ultrafiltration and protein 
quantitation kit. Using an ultrafiltration tube (MWCO 300 kDa), NPs and unencapsulated Lira 
were separated by ultrafiltration at 300×g for 20 min at room temperature. Free Lira was 
collected in the subnatant and measured for concentration by protein quantitation kit with an 
intensity-concentration standard curve of Lira. Similarly, for checking the pass ratio (PR) of the 
ultrafiltration device, the NPs solution was replaced by free Lira at one third of concentration 







[𝐿𝑖𝑟𝑎 𝑝𝑎𝑠𝑠𝑒𝑑 𝑡ℎ𝑟𝑜𝑢𝑔ℎ 𝑡ℎ𝑒 𝑚𝑒𝑚𝑏𝑟𝑎𝑛𝑒]
[𝐿𝑖𝑟𝑎 𝑜𝑓 𝑤𝑜𝑟𝑘𝑖𝑛𝑔 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛]/3
 
 
EE % = (1 −
[𝐿𝑖𝑟𝑎 𝑖𝑛 𝑠𝑢𝑏𝑛𝑎𝑡𝑎𝑛𝑡]𝑃𝑅
[𝐿𝑖𝑟𝑎 𝑜𝑓 𝑤𝑜𝑟𝑘𝑖𝑛𝑔 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛]/3
) × 100% 
 
2.4 FT-IR analysis of the interaction between components 
All the suspensions were lyophilized to make solid dry sample. Mixed with KBr, solid samples 
were grinded thoroughly before pressing into pellets. Pressed discs were analyzed in       at 
20 scans per sample from 500 to 4000 cm−1.    
 
2.5 In vitro release profile of liraglutides 
The dialysis tube was placed in 50 ml centrifuge tube with 9 ml 1×PBS (0.05% w/v sodium 
azide), where the membrane part was immersed in the media. Following that 1 ml sample was 
pipetted into the dialysis tube, 50 ml centrifuge tube was sealed and incubated at 37 ℃ on a 
shaker at 100 rpm. Release samples (200 μL) were collected at specific time point of 1, 2, 3, 4, 
5, 6, 7, 8-day, followed by refilling fresh media (200 μL) for maintenance of the media volume. 
The concentration of collected samples were determined by protein quantitation kit. The 
accumulative release at n-th point was calculated as follows. 
 
Accumulative Release % =
[𝐿𝑖𝑟𝑎]𝑛 × 10 mL + ∑ [𝐿𝑖𝑟𝑎]𝑘 × 0.2 mL
𝑛−1
𝑘=1
[𝐿𝑖𝑟𝑎]0 × 1 mL
× 100% 
 
2.6 In vivo biodistribution and retention 




and NPs-3 (TA 1 or 2 mg/mL; Al3+ 0.05 mg/mL; Lira 1 mg/mL). Total of 200 μL NPs suspension 
or 200 μL free Cy 7.5- Lira was administrated on T2B mice through intraperitoneal (i.p.) 
injection at dose of 500 μg/kg. The distribution and intensity of Cy7.5-Lira was tracked by IVIS 
image system (Progama, US) at ex 780 nm and em 810 nm at post-injection timepoint of 0.5, 1, 
3, 6, 24, 48, 72, 96, 120 and 144 -h. Correspondingly, around 200 μL blood sample was taken 
from canthus venous plexus right after imaging and 150 μL of sample was pipetted into 96-well 
plate. Similarly, the sample-loaded plate was imaged by IVIS image system (ex 780 nm; em 
810 nm). 
 
2.7 Potency of nanoparticles on managing glucose level 
The efficacy of Lira-loaded NPs was evaluated by glucose level monitoring in T2D mice. T2D 
mice, which are set by leptin receptor-deficiency, are randomly divided into 4 groups with 5 
mice in each. These groups were injected with low dose of free Lira solution (2 mg/kg), high 
dose of free Lira solution (10 mg/kg), high dose of NPs-1, 2, 3 (10 mg/kg) and 1×PBS 
respectively. Another group of healthy mice were set as the control group. At specific timepoints 
of 6, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156-h post injection, blood from tail 
vein were sampled and measured for glucose concentration through blood glucose meter 
(OneTouch® UltraVue, Johnson, USA). 
 
2.8 Statistical analysis 
All values are expressed as mean ± S.D. Comparisons among all groups were evaluated using 




US), and p < 0.05 was considered to be statistically significant. 
 
3. Results and discussion 
3.1 Assembly of nanoparticles involves flash nanocomplexation (FNC) 
Polyphenol-protein (peptide) interactions has been widely studied due to their application in 
food industry and biomedical field [12-15]. In most cases, protein and polyphenol form 
insoluble complex, leading to macroscopic precipitation in mixed solution. The phenomenon 
of aggregation was attributed to the (i) change of microenvironment of residues on periphery 
side of proteins or peptides; and (ii) crosslinking between complexes by hydrogen bonding. The 
non-covalent interaction between polyphenol and peptide, which involves hydrogen bonding 
and Van der Waals force, damage of hydration shell without change of secondary structure and 
exposure of hydrophobic domain of peptides[16]. Therefore, driven by hydrophobic force 
thermodynamically, protein-polyphenol complexes tend to aggregate. Further, complexes 
continuously crosslink due to the interaction between excess phenol groups and peptides that 
are not saturated by hydrogen bonds yet.  
 
However, the complex can be dissociated with the change of conditions like pH and temperature. 
Tannic acid (TA), a natural polyphenol with pKa around 6, forms strong interaction with peptide 
in acidic condition (pH<6), but in human body with pH of 7.4, the partial ionization of phenol 
groups weaken the hydrogen bonding system and allow for peptide escape[17].  
 




Liraglutide (Lira) based on TA-peptide interaction, whereas the natural property of aggregation 
of TA-Lira complex pose great challenge on injectability. To address it, we introduced the Al3+ 
in nanoparticles preparation, which forms coordinate bonds with TA[18]. Importantly, this 
coordinate reaction, which is common for trivalent metal ions, gives transparent solution and 
does not induce aggregation. Serve as a surfactant, Al3+ ions ‘quench’ the excess phenol groups 
and thus keep the complexes from further crosslinking. 
 
 
For severing better as a role of surfactant, Al3+ were required to be mixed with TA and Lira 
homogenously. To achieve this, we utilized the FNC technology, where all the solutions of 
components are introduced into micro mixing chamber with high flow rate. As a technology 
generating turbulence for rapid and homogenous mixing, FNC has been broadly applied in 
nanoparticles preparation[19-21]. Based on thermodynamic availability, through FNC, we aim 
to optimize and control the process of assembly kinetically. Low flow rate of 1 ml/min leads to 
heterogenous mixing, thus causing multiple species of components in the solution. It was 
observed by DLS spectrum of multiple peaks range from 43.7 nm to 5030 nm (Fig. 2A). The 
5030 nm peak, which indicates aggregation, was resulted from absence of Al3+ in some local 
regions during the mixing. With the increase of flow rate, the condition of mixing got improved 
and the possibility of Al3+ being evenly dispersed increased greatly. The micro-sized peaks 
faded with growth of flow rate and got disappeared when it reached 20 mL/min. The main peak, 
which stably remained at around 55 nm, indicated that the assembly of desirable nanoparticles 




observed by DLS (Fig. 2B). Significant difference of homogeneity prepared at different flow 
rate (1, 10, and 25 mL/min) can be observed. The aggregation (crosslinked dark substance) 
existed in sample of 1 and 10 mL/min, but not in that of 25 mL/ml. 
 
3.2 Controlled release of liraglutide from nanoparticles 
Due to the strong interaction between TA and peptides, Lira was successfully encapsulated at 
an ideal encapsulation efficiency of 98%. To demonstrate the interaction between components, 
FT-IR was operated and the change of shape and position of peaks was observed. Affected by 
the interaction between TA with Lira or Al3+, the wide peak at 3391.8 cm-1, indicating the phenol 
groups on TA, changed the shape and shift to wavenumber of around 3415 cm-1 in both cases, 
which verified the hydrogen and coordinate bonding on phenol groups (Fig. 3A). 
 
As a critical factor in drug release, the amount of surface area of nanoparticles needs to be 
guaranteed for a sustained release. To maintain the surface area, it requires that nanoparticles 
should have stable size and avoid aggregation in vivo. To measure that, we place the NPs 
suspension in 1×PBS and monitor the size change for 7 days. No dramatic change was observed 
from DLS in all three formulations that the size change was within the range of 10% over 7 
days (Fig. 3B), where the negative surface charge (-26.1±0.8 mV) may contribute to the size 
stability. 
 
Based on the understanding of the release mechanism that hydrogen bonding is weakened by 




amount of TA. From the in vitro release study, all the formulations achieved sustained release, 
and furthermore, the different formulations show obviously different release behavior, 
including different amount of burst release and sustained release rate (Fig. 3C). With highest 
amount of TA (2 mg/mL), NPs-3 shows lowest burst release of 12% and slowest sustained 
release (60 % released for 8 days). We attributed it to the high density of phenol groups, which 
trap the Lira and prevent the release. On the other hand, as expected, formulation with lowest 
amount of TA (0.5mg/ml, NPs-1) showed huge burst release of 30 % and 80 % got released 
over 8 days. This capacity of release regulation indicates the great potential that this ternary 
system may satisfy the different requirements for drug release rates in clinical trails. 
 
3.3 In vivo biodistribution and retention 
To further confirm the release behavior, biodistribution and retention in vivo was analyzed and 
it showed the similar trend to the situation in vitro. Besides fluorescence-based animal imaging, 
blood sample was also collected for assessment of the content of Lira in circulation. The signal 
for free Cy-7.5 labelled Lira reached the peak at 3 h and attenuated rapidly within 24 h, which 
can be observed from both animal imaging and blood imaging (Fig. 4A). After 48 h, the signal 
was weak in animal imaging and can be hardly detected in blood sample, indicating the quick 
degradation and body clearance of free Lira. In contract, NPs formulation with same dose of 
Lira showed longer retention time. For signal of NPs-2, It took 120 h to fall to the same level 
as free Lira did at 24 h and for NPs-3, it took even longer time. Notably, the burst release within 
1 h in NPs-3 is less than that in NPS-2, which can be observed from the blood sample and signal 




certain degree of enhancement of total signa, compared with the starting time point (Fig. 4C). 
We attribute this unexpected phenomenon to the fluorescence quench that the Cy-7.5 groups on 
Lira quenched at high concentration inside nanoparticles. With the proceeding of release, these 
quenched Cy-7.5 groups were activated again when escaping from the NPs. Nevertheless, the 
process of drug diffusion can still be monitored from animal imaging and the retention time can 
be assessed from blood sample. Although the duration of release was different between in vivo 
and in vitro due to the complexity in In vivo environment, trends of release behavior, including 
difference of burst release amount and sustained release rate among formulations, match well 
with each other. 
    
3.4 Treatment potency of nanoparticles on managing glucose level 
Corresponding to the biodistribution and drug retention study, treatment efficacy was studied 
on db/db model mice for analyzing the practical potency of different NPs formulations. Db/db 
mice were administrated with NPs-1, 2 and 3 at a single dose of 10 mg/kg respectively. Two 
positive control groups were set by injection with free Lira (2 mg/kg; 10 mg/kg) and blank 
control was set by injection with PBS. For all the drug treated groups, glucose level decrease 
rapidly to normal level within 6 h, where the burst release of NPs formulation guaranteed the 
effective concentration (Fig. 5A). In both positive control groups, glucose level began to 
rebound at very early timepoints of 6-h post injection and recover to original level within 48 h. 
Although the high dose of free Lira (10 mg/ml) leaded to a half-recovery time of more than 24 
h, it was shorter than NPs formulation, especially compared with NPs-3. For NPs formulations, 




more than 60 h to start to rebound and more than 150 h to recovery to original level. As expected, 
NPs-1 and NPs-2, the formulations with faster release, made glucose level recover to 50% of 
origin by shorter time of around 30 and 40 h respectively. The differences of treatment outcome 
among NPs formulations and the different retention time in circulation mutually confirmed and 
it indicate the capacity for tuning release behavior both in vitro and in vivo.  
 
Also, weight change was monitored during the treatment, since Lira is also a GLP-1 drug 
approved to treat obesity (Fig. 5B). From the data, all the treated groups showed weight control 
potency and compared with free Lira group, NPs-1 and NPs-2 revealed slight advantage. 
Remarkably, unlike other groups, NPs-3 helped maintain the decreased body weight in the first 
4 days, indicating complete containment on body weight. It may be attributed to the most 
sustained release behavior of NP-3.  
 
4. Conclusion 
Here we report a nanoparticle platform for prolonged and controlled release of therapeutic 
peptides, composed of tannic acid, peptides and trivalent ion. In this typical ternary system, 
hydrogen bonding between tannic acid and peptides serve as the major interaction in particle 
forming and aluminum ions serve as surfactant. The technology of flash nanocomplexation 
(FNC) played an important role in nanoparticle preparation through kinetic control, where rapid 
homogeneous mixing prevent aggregation and thus made formulations injectable. By in vitro 
release study and retention study in vivo, this system showed great capacity of sustained release 




ionization of phenol groups on tannic acid weakened the hydrogen bonding, amount of burst 
release and sustained release rate were controlled by tuning the component amount of tannic 
acid. The enhancement of drug potency in treatment study further confirm that the sustained 
release of this system worked well in vivo. Importantly, in the complexed in vivo condition, 
treatment outcome still revealed obvious difference among different formulations, which 
indicates the capacity of pharmacodynamics tuning in vivo. To sum up, this nanoparticle 








Fig 1. Schematic diagram nanoparticles and preparation. (A) Schematic diagram of 
Lira/TA/Al3+ nanoparticles preparation based on FNC technology and demonstration of 
inside interactions; (B) Formation of aggregation in absence of Al3+; (C) Formation of 









Fig 2. Size and distribution of nanoparticles. (A) Effect of volumetric flow rate of FNC on size 
distribution of NP-3 formulation. Curves (filled circles) and bars represent mean ± S.D. (n= 3) 
of measurements from three different preparations; (B) TEM images of Lira-loaded NP-3 







Fig 3. Characterization of Lira-loaded nanoparticles. (A) FT-IR spectrum of TA, AlCl3, 
liraglutide, TA/Al3+ complex, TA/liraglutide complex and TA/liraglutide/Al3+ nanoparticles; (B) 
Colloidal stability of formulations indicated by size change over a month; (C) In vitro release 







Fig 4. Sustained release of Lira from formulations in Balb/c mice post i.p. injection. (A) In vivo 
fluorescence imaging of mice at different time points following single i.p. injection of Cy 7.5-
labeled free Lira and Lira loaded nanoparticles at dose of 500 μg/kg; (B) Fluorescence imaging 
at different time points of blood samples collected from mice administrated with Cy 7.5-labeled 
free Lira or Lira-loaded nanoparticles. (C) Quantification of fluorescence intensity of the Cy 
7.5-labeled free Lira and Lira-loaded nanoparticles in peritoneal cavity given by IVIS images 






Fig. 5. In vivo efficacy of exendin-4-loaded nanoparitcles in db/db mice (T2D model). (A) 
Blood glucose levels of db/db mice following single i.p. injection of free Lira (2 mg/kg; 10 
mg/kg) or Lira-loaded NP-1, 2 and 3 (Lira of 10 mg/kg). Control groups were PBS-treated; (B) 
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